Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy

Christ, Sebastian M; Schettle, Markus; Seiler, Annina; Guckenberger, Matthias; Blum, David; Andratschke, Nicolaus; Hertler, Caroline

Abstract: Background Radiotherapy plays an important role for symptom control in advanced stage cancer patients. Yet patients need to be carefully selected, and its use and benefits must be weighed against time spent under treatment and patient priorities in the last phase of life. In this study, we assess prevalence, indications and outcomes of radiotherapy close to death. Methods We screened all radiotherapy treatments performed at the Department of Radiation Oncology of the University Hospital Zurich between January 2010 and December 2019 to identify those which occurred near patients’ end-of-life. Analyzed data was extracted from the database of the Comprehensive Cancer Center Zurich, the treatment planning system Aria® and the electronical medical records system KISIM®. Results Within 60 days of death, 377 radiotherapy courses were prescribed to 280 patients, which constitutes 3.4% of all radiotherapy courses administered over the last decade at our department. Within 60-31, 30-8, and 7-0 days to death 164, 159, and 54 radiotherapy courses were prescribed, respectively. The most frequent treatment sites were brain (N = 122, 32%) and bone (N = 119, 32%), and there was no statistically significant difference in treatment site between the three sub-groups. The most common regimen was 10x3Gy (N = 130, 35%) in all three sub-groups (p = 0.23). Radiotherapy finished more than one week before death was associated with high completion rates (>80%) and treatment benefit (>55%). Conclusion Patient selection and survival prognostication remains challenging for radiation oncologists. While radiotherapy achieved high completion and success rates until one week before death, treatment within one week of death should be restricted to carefully selected patients or avoided altogether.

DOI: https://doi.org/10.1016/j.ctro.2021.06.010

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-208739
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:
Christ, Sebastian M; Schettle, Markus; Seiler, Annina; Guckenberger, Matthias; Blum, David; Andratschke, Nicolaus; Hertler, Caroline (2021). Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy. Clinical and Translational Radiation Oncology, 30:26-30.
Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy

Sebastian M. Christ a,*, Markus Schettle a, Annina Seiler a,b, Matthias Guckenberger a, David Blum a, Nikolaus Andratschke a, Caroline Hertler a

a Department of Radiation Oncology and Competence Center for Palliative Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland
b Department of Consultation Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland

ARTICLE INFO

Keywords:
End-of-life
Palliative
Radiotherapy
Cancer care

ABSTRACT

Background: Radiotherapy plays an important role for symptom control in advanced stage cancer patients. Yet, patients need to be carefully selected, and its use and benefits must be weighed against time spent under treatment and patient priorities in the last phase of life. In this study, we assess prevalence, indications and outcomes of radiotherapy close to death.

Methods: We screened all radiotherapy treatments performed at the Department of Radiation Oncology of the University Hospital Zurich between January 2010 and December 2019 to identify those which occurred near patients’ end-of-life. Analyzed data was extracted from the database of the Comprehensive Cancer Center Zurich, the treatment planning system Aris® and the electronic medical records system RisMed.

Results: Within 60 days of death, 377 radiotherapy courses were prescribed to 286 patients, which constitutes 3.4% of all radiotherapy courses administered over the last decade at our department. Within 60–31, 30–8, and 7–0 days to death 164, 159, and 54 radiotherapy courses were prescribed, respectively. The most frequent treatment sites were brain (N = 122, 32%) and bone (N = 119, 32%), and there was no statistically significant difference in treatment site between the three sub-groups. The most common regimen was 10×3Gy (N = 130, 35%) in all three sub-groups (p = 0.23). Radiotherapy finished more than one week before death was associated with high completion rates (>80%) and treatment benefit (>50%).

Conclusion: Patient selection and survival prognostication remains challenging for radiation oncologists. While radiotherapy achieved high completion and success rates until one week before death, treatment within one week of death should be restricted to carefully selected patients or avoided altogether.

Introduction and background

Radiotherapy (RT) constitutes a treatment modality with a very favorable risk profile for symptom control in advanced stage cancer patients [1,2]. Palliative RT has proven to be effective for the treatment of painful bone metastasis and for stabilizing symptomatic as well as emergency situations like hemoptysis or spinal cord compression [3–6].

Several studies have shown that experienced physicians tend to systematically overestimate patients’ survival, even when prognostic factors and scoring systems are employed [7,8]. This may contribute to both the prescription of longer RT courses despite the recommendation for hypofractionated schedules as well as potentially overly aggressive treatment regimens. As a result, RT may be administered near the end-of-life (EoL) without having a positive effect on quality-of-life (QoL) [2,9,10]. Instead, such treatments carry the risk of depriving patients of valuable EoL time spent outside hospitals close to their loved ones, realizing key priorities in the last phase of life. Hence even though the World Health Organization recommends RT in the management of cancer patients in adults as well as adolescents, and the guidelines of the European Society of Medical Oncology and the American Society of Clinical Oncology intend to help navigate treatment decisions in advanced stage cancer patients, selecting the right palliative treatment strategy for any individual patient remains challenging for treating physicians. Appropriately managed, palliative RT regimens, even when prescribed close to death, have the potential to improve QoL, as, for example, emergent or analgesic effects of RT may start to take effect.

* Corresponding author at: Department of Radiation Oncology and Competence Center for Palliative Care, University Hospital Zurich, Bürkistrasse 100, 8091 Zurich, Switzerland.

E-mail address: sebastian.christ@uzh.ch (S.M. Christ).

https://doi.org/10.1016/j.ctro.2021.06.010

Received 15 March 2021; Received in revised form 27 June 2021; Accepted 29 June 2021
Available online 4 July 2021

2405-6308/© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
hours or days after treatment has begun or been completed [11–14].

As the prognostication of patient survival remains an inexact science and as the commonly used EoL cut-off of 30 days seems to have been chosen arbitrarily, this single-institution analysis at a tertiary comprehensive cancer center in Switzerland sits at comparing EoL RT in patients according to the historical definition with groups of patients who had a longer and a shorter prognosis. For all three groups, we assess the prevalence, review the indications and treatment rationales, and quantify the outcomes of EoL RT.

Materials and methods

We screened all RTs conducted at the Department of Radiation Oncology of the University Hospital Zurich between January 2010 and December 2019 to identify those which were occurred near EoL. The list of analyzed patients was extracted and compiled using the Record and Verify System Aria® (Version 15, Varian®), the central database and tumor registry of the Comprehensive Cancer Center Zurich.

Demographic patient data were retrieved from the hospital’s electronic medical records system KISIM®. Extracted variables included gender, tumor histology, date of birth, date of death, treatment modality, dates of treatment, metastatic status at primary diagnosis, place of death, treatment intent, treatment completion, reason for treatment discontinuation, treatment indication, treatment site, treatment outcome, clinical performance status, and the existence of an advance healthcare directive at the time of treatment start. If missing, the performance status was derived from available data. Treatment outcome per RT course was assessed qualitatively via a thorough review of electronic medical records and all available follow-up information: Treatment benefit was defined as pre-therapeutic symptom load not having worsened (“symptom control”) or having been improved (“symptom improvement”). Data on treatment dates, fractionation and dosage schedules were obtained from Aria®. All data was encoded. This review, as part of a project series, was approved by the Swiss Cantonal Ethics Committee (BASEC ID #2019-02488).

Descriptive statistics were computed for all demographic and treatment variables. EoL RT patients were subsequently stratified in order to compare and contextualize outcomes in three different patient subgroups who received RT 60–31 days, 30–8 days and 7–0 days before death. For multiple sub-group comparison, the non-parametric Kruskal-Wallis test was used. Statistical significance was set at p < 0.05. To facilitate comparability with other studies, the nomenclature RTDp, increasingly commonly applied in the literature, was consistently used to label treatments taking place within a certain time interval in days before death [15]. EoL RT was defined as taking place within 60 days of death for the purposes of this analysis. For all statistical analysis, the statistical software package Stata® (Version v16.1) was utilized.

Results

Contextualization of patient population

Between 2010 and 2019, 10,980 patients received 22,164 RT courses at our department, 64.8% (N = 14,370) and 35.2% (N = 7,794) of which had a curative and a palliative intent, respectively. The 280 patients having received EoL RT courses within the last decade, thus constitute 2.6% of all patients treated at our department. The 370 EoL RT courses with a palliative intent represent 4.8% of all prescribed palliative RT courses. The 7 EoL RT courses with a curative intent make up a negligible proportion of 0.05% of all prescribed curative RT courses over the past decade at our department.

Patient characteristics

For the 280 patients having received EoL RT, the median age at primary diagnosis was 65 (interquartile range [IQR], 55–72) years, with the majority of patients being male (N = 168, 66%). All patients had a histologically verified cancer diagnosis. The two most common primary cancer entities were lung (N = 123, 44%); non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and mesothelioma) and melanomas (N = 76, 27%), accounting together for about 70% of all cases. More than two thirds of patients were metastatic at primary diagnosis, with the most common metastatic sites being lung (N = 82, 44%) and bone (N = 74, 40%). The performance status was higher or equal to 70% of the Karnofsky Performance Score (KPS) in 57% (N = 160) of patients at the time of consult when treatment was prescribed. The median interval from the time of primary diagnosis to RT start was 7.7 (IQR, 1.4–20.8) months. Forty-five (16%) patients had completed an advance healthcare directive prior to RT start. For the majority of patients (N = 184, 66%), the place of death was the inpatient setting. Thirty-five (13%), 23 (8%), and 8 (3%) patients died at home, in a nursing home and at a hospice, respectively. Thirty (11%) patients were lost to follow-up; the date of death was assessed through death registries. Patient characteristics are shown in Table 1.

Treatment characteristics

A total of 377 EoL RT courses was prescribed to 280 patients (mean: 1.35 courses per patient, median: 1 course per patient, range: 1–6 courses). An interdisciplinary tumor board was involved in the treatment decision in 38% (N = 142) of all prescribed RT courses. The treatment intent was palliative in N = 370 (98%) RT courses. A curative treatment regimen was prescribed in seven courses (2%) for lung, head & neck, brain and esophageal cancer patients. In more than 70% of treatment courses, the RT indication was pain or symptomatic brain/spinal metastasis (N = 273, 73%). Less frequently, indication was dyspnea/hemoptysis, asymptomatic brain/spinal metastasis or bleeding.

Table 1

| Data variables                                      | Patients (n = 280) |
|-----------------------------------------------------|-------------------|
| Age at primary diagnosis in years, median (IQR)     | 65 (55–72)        |
| Male gender, n (%)                                  | 186 (66)          |
| Primary tumor site, n (%)                           |                   |
| Lung                                                | 123 (44)          |
| Melanoma                                            | 76 (27)           |
| CNS                                                 | 32 (11)           |
| Head & Neck                                         | 13 (5)            |
| Colorectal                                          | 8 (3)             |
| Other1                                              | 28 (10)           |
| Presence of metastasis at primary diagnosis, n (%)  | 187 (67)          |
| Metastatic sites at primary diagnosis, n (%)        |                   |
| Lung                                                | 82 (44)           |
| Bone                                                | 74 (40)           |
| Brain                                               | 51 (27)           |
| Liver                                               | 46 (25)           |
| Other2                                              | 145 (78)          |
| Karnofsky performance status (KPS), n (%)           |                   |
| ≥ 70                                                | 160 (57)          |
| < 70                                                | 120 (43)          |
| Overall survival from date of primary diagnosis in months, median (IQR) | 7.7 (1.4–20.8) |
| Advance healthcare directive prior to RT start, n (%) | 45 (16)          |
| Place of death, n (%)                               | 184 (66)          |
| Inpatient                                           | 35 (13)           |
| Home                                                | 23 (8)            |
| Unknown                                              | 8 (3)             |

Abbreviations: CNS — Central nervous system; IQR — Interquartile range; RT — Radiation therapy.
1 Includes breast, bone/soft tissue, esophageal, gynecological, hematologic, liver, thyroid, and pancreatic cancer.
2 Includes adrenal glands, leptomeningeal disease, lymph nodes, mediastinum, orbita, skull base, spinal cord, and visceral organs.
Brain and bone were the most common treatment sites comprising more than 60% (N = 241) of all courses. In 23% (N = 85) of courses the primary tumor was irradiated. The median number of fractions was 10 (IQR, 5–10), the median dose per fraction was 3 (3–4) Gy, and 85% (N = 321) of RT courses consisted of more than 5 fractions. Median duration of RT was 11 (IQR, 6–16) days. With 83% (N = 311) the large majority of EoL RT courses was completed. When a RT course had to be discontinued, a general deterioration of the patient’s performance status due to disease progression was identified as the cause in 77% (N = 51) of cases. The treatment aim was reached in N = 197 of RT courses, having led to a patient benefit in 52% of treatments. Treatment characteristics are summarized in Table 2.

Sub-group analysis

For sub-group analysis, the data on RT courses was stratified using time of RT application to create three distinct groups: treatments within 60 to 31 days before death (RT<sub>60-31</sub>), 30 to 8 days before death (RT<sub>30-8</sub>), and 7 to 0 days before death (RT<sub>D7</sub>). This resulted in N = 164 (43.5%) courses in the RT<sub>60-31</sub> group, N = 159 (42.2%) in the RT<sub>30-8</sub> group, and N = 54 (14.3%) in the RT<sub>D7</sub> group. Median patient age at time of radiotherapy treatment was 66 (IQR, 56–73), 65 (IQR, 53–73), and 64 (IQR, 56–72) for patients receiving RT<sub>60-31</sub>, RT<sub>30-8</sub>, and RT<sub>D7</sub>, respectively. No statistically significant difference was observed with respect to patient age (p = 0.47). Two thirds of courses were administered to male patients: 67.1% in RT<sub>60-31</sub>, 67.3% in RT<sub>30-8</sub>, and 66.7% in RT<sub>D7</sub> (p = 1.00). Between the three sub-groups no statistically significant difference in KPS was observed (p = 0.59). A tumor board was involved in the treatment decision of 36.0% (N = 59), 41.5% (N = 66), and 31.5% (N = 17) of RT<sub>60-31</sub>, RT<sub>30-8</sub>, and RT<sub>D7</sub> treatments, respectively (p = 0.35). Between the three sub-groups, there was also no significant difference in treatment indications (p = 0.52): pain was the most common indication in RT<sub>60-31</sub>, RT<sub>30-8</sub>, and RT<sub>D7</sub>, with N = 72 (43.9%), N = 71 (44.7%), and N = 25 (46.3%), respectively. Symptomatic brain/spinal metastasis was the second most common indication and represented 25.6% (N = 42), 30.2% (N = 48), and 27.8% (N = 15) in RT<sub>60-31</sub>, RT<sub>30-8</sub>, and RT<sub>D7</sub>, respectively. Dyspnea/haemoptysis, asymptomatic brain/spinal metastasis, bleeding and other indications were less common in all three sub-groups. There was no statistically significant difference between fractionation schedules either, with a median of 10 fractions prescribed to patients in all three sub-groups (p = 0.23). Statistically significant differences between the three sub-groups were observed with respect to RT course discontinuation rate, which was 6.1% (N = 10) and 17.0% (N = 27) in the RT<sub>60-31</sub> and RT<sub>30-8</sub> sub-groups, respectively, compared to 53.7% (N = 29) in the RT<sub>D7</sub> sub-group (p < 0.001). Treatment benefit was also significantly different between sub-groups (p < 0.001): While RT courses were deemed beneficial in 81.7% (N = 134) and 58.5% (N = 93) of RT<sub>60-31</sub> and RT<sub>30-8</sub> sub-groups, respectively, treatment failure in RT<sub>D7</sub> was 94.4% (N = 51). For a tabulation of the variables for the three sub-groups, see Table 3.

Table 2

| Data variables | RT courses (n = 377) |
|---------------|---------------------|
| RT courses per patient, mean; median (range) | 1.35; 1 (1–6) |
| Tumor board involvement in RT decision, n (%) | 142 (38) |
| Palliative RT treatment intent, n (%) | 370 (98) |
| Treatment indication, n (%) | 12 (3) |
| Pain | 168 (45) |
| Symptomatic brain/spinal metastasis | 105 (28) |
| Dyspnea/haemoptysis | 93 (9) |
| Asymptomatic brain/spinal metastasis | 32 (8) |
| Bleeding | 20 (5) |
| Definitive<sup>1</sup> | 7 (2) |
| Other<sup>2</sup> | 12 (3) |
| Treatment site, n (%) | 122 (32) |
| Brain | 119 (32) |
| Bone | 85 (23) |
| Soft tissue | 29 (8) |
| Lymph node | 12 (3) |
| Other<sup>3</sup> | 10 (3) |

<sup>1</sup> Includes one case of chemo-sensitization and one case of radiochemotherapy for glioblastoma.
<sup>2</sup> Includes cholestasis, inferior vena cava syndrome, among others.
<sup>3</sup> Includes adrenal glands, lung, mediastinum, orbita, skull base, spinal cord, and visceral organs.

Discussion

Summary of key results

Within 60 days of death, 377 RT courses were prescribed to 280 patients, which represents 3.4% of all RT courses prescribed over the last decade at our department. The most frequent EoL RT sites were brain (32%) and bone (32%). Of all prescribed EoL courses, 83% were completed as planned. Treatment was deemed beneficial for patients in 52% EoL courses. Treatment discontinuation rates and patient benefit after RT were favorable for all patients except when RT was performed in their last week. The most commonly prescribed RT regimen was 10x36Gy, independently of the three sub-groups.

Treatment intent

No significant differences with respect to basic patient and treatment characteristics were identified in the three sub-groups RT<sub>60-31</sub>, RT<sub>30-8</sub> and RT<sub>D7</sub>. No statistically significant difference in treatment indications was observed between sub-groups, providing no evidence for the hypothesis that patients who were treated closer to EoL had a higher proportion of highly palliative or emergent RT indications. The patients who were prescribed a curative EoL RT died of causes not related to RT. It remains challenging for physicians to predict and differentiate patient-individual life expectancy between 1 and 2 months, few weeks and only one week and to identify patients who may or may not qualify for and benefit from EoL RT.

Fractionation schedules

This is also supported by the fact that prescribed RT courses consisted of 10 or more fractions in almost 60% of cases and were associated with a median of 10 days spent under therapy. Prescribed regimens did not differ among sub-groups (p = 0.23). Such RT schedules have widely been considered too long for an EoL situation<sup>10</sup>, yet remain common and were similarly reported in other studies: Guadagnolo et al. (2012) found that 20% of patients in a large population-based cohort of elderly patients who received RT within 30 days of death spent 10 days under...
Table 3
Comparison of three different treatment subgroups.

| Data variables | RTD10-31 | RTD20-80 | RTD4-0 | χ² prob. |
|----------------|----------|----------|--------|----------|
| # of RT courses (n, %) | 164 (43.5) | 159 (42.2) | 54 (14.3) | 0.4658 |
| Age at RT (median, IQR) | 66 (56-73) | 65 (53-73) | 66 (56-72) | 0.9963 |
| Male gender (n, %) | 110 (67.1) | 107 (67.3) | 36 (66.7) | 0.5932 |
| KPS at RT start (n, %) | 107 (89) | 89 (56) | 32 (40.7) | 0.3545 |
| Tumor board decision (n, %) | 110 (70) | 107 (67) | 36 (67) | 0.5156 |
| Treatment intent (n, %) | 72 (46.9) | 66 (55) | 25 (80) | 0.5235 |
| Pain | 11 (4.2) | 10 (4.2) | 7 (14.2) | 0.2809 |
| Symptomatic brain/spinal metastasis | 11 (4.2) | 10 (4.2) | 7 (14.2) | 0.2809 |
| Dyspnea/hemoptysis | 10 (4.2) | 10 (4.2) | 7 (14.2) | 0.2809 |
| Definitive | 10 (4.2) | 10 (4.2) | 7 (14.2) | 0.2809 |
| Others | 10 (4.2) | 10 (4.2) | 7 (14.2) | 0.2809 |
| Proportion of EoL, period spent under therapy (median %, IQR) | 10 (4.2) | 10 (4.2) | 7 (14.2) | 0.2809 |

Abbreviations: EoL — End of life; IQR — Interquartile range; KPS — Karnofsky Performance Score; RT — Radiotherapy; RTDxx — Radiotherapy having taken place xx days before a patient’s death.

Discontinuation rate

The majority of the EoL RT courses (83%) were completed as planned. Of the 377 prescribed EoL RT courses, 66 stopped early, resulting in an effective discontinuation rate of 17%. Though comparability is challenging due to varying definitions of EoL and patient selection, when putting this figure into perspective to other studies having focused exclusively on patients with palliative RT near EoL, e.g., by using a certain cut-off date, this rate is low. Berger et al. (2014) reported a discontinuation rate of 78% in 52 cancer patients who died within 30 days of end of RT. Similarly, Toole et al. (2012) found a RT discontinuation rate of 52% in a cohort of 63 patients who died shortly after RT [9,17]. When compared to studies assessing the rate of Eol RT in a broader cohort of patients treated with palliative RT, the discontinuation rate in our study was comparable. While Wu et al. (2019) and Grade et al. (2019) reported discontinuation rates of 12% and 12.6% in 518 and 214 cancer patients, respectively, Anshushag et al. (2015) reported 18% of all RTs cancelled in 616 cancer patients [6,15,18]. For a comparative overview of selected studies, see Table 4. When looking at different sub-groups, course completion was only 46.3% in the RTD seven sub-group, which was significantly lower than in the RTD thirty (83.0%) and RTD sixty-one (93.9%) sub-groups (p < 0.001).

Treatment benefit

Upon reviewing the patients’ medical records, more than one third of the EoL RT courses achieved the intended palliative treatment benefit (52%). When looking at the three different sub-groups, a beneficial outcome was observed in only 6% of RT courses in the RTD seven sub-group, which is in strong contrast to the benefit rates of 85% in the RTD thirty sub-group and 59% in the RTD sixty-one sub-group (p < 0.001). This low benefit rate is not surprising and indicates that many patients treated within one week of death had little benefit in the form of symptom control or QoL improvements. However, the results here underline the suggestion that RT may be a valuable treatment option even in patients with a life expectancy of 30 days only, where a palliative treatment benefit was achieved in more than one third of the patients in this cohort.

Survival prognostication

These findings reinforce the need to develop a comprehensive prognostic assessment to improve accuracy of physicians’ prediction of survival and weigh options of symptom control through EoL RT versus best supportive or hospice care. It is indicated that institutions systematically scrutinize their clinical practice and pattern of care by reviewing the use of palliative RT in patients at the EoL, as some centers have already done [15]. One additional metric seen in the literature to compare across studies is RTD sixty, the proportion of patients having received RT within one month of death. There is even recommendation that RTD sixty should lie below 10%, which may be challenged on the basis of the EoL RT completion and success rates reported in this study, however [15]. In comparable studies, the rate of RTD thirty ranges between 8% and 100%, depending on the patient cohort analyzed, the cut-off time point chosen for EoL analysis as well as the denominator for the comparative analysis (see Table 4). RTD sixty in this patient group was 57% when compared to patients treated within 2 months of death. When put into perspective with all palliative RT courses prescribed at our tertiary center over the last decade, RTD sixty was 2.7%.

Advance care planning and place of death

Today, advance care planning and patient-centered care are considered an important pillar of cancer care [19]. Only 16% of patients had completed their advance healthcare directive before consultation for RT. Despite this, treating physicians should acknowledge that cancer care at the EoL includes highly individual decisions, with QoL improvement often being a top priority. When looking at place of death, the larger proportion of 66% of patients died in an inpatient setting, either on the palliative care wards or in another acute care hospital bed. Given that the analyzed patients represent a selected and vulnerable group suffering from incurable, metastatic cancer close to the EoL, it is yet not surprising that the proportion of patients dying in an acute care facility is higher than the Swiss population average which is close to 41% [20].
Table 4
Overview of selected studies examining the use of palliative RT near death.

| First author (year) | Patient cohort | Time period | Primary cancer type | RT used, n (%) | Discontinued RT treatments, n (%) |
|---------------------|----------------|-------------|---------------------|---------------|-----------------------------------|
| Wu et al. (2019) [15] | 581 cancer patients treated with palliative RT | 2012–2016 | All histologies | 125/24% | 63/12% |
| Gade et al. (2019) [6] | 214 cancer patients treated in 238 palliative RT courses | 2014 | All histologies | N/A | 37 (12.6%) |
| Aushahmou et al. (2015) | 616 cancer patients treated with RT, CT or RCT | 2005, 2009 | All histologies | 61 (8%) | 11 (18%) |
| Ellisworth et al. (2014) [21] | 399 patients receiving RT for bone metastasis | 2007–2012 | All histologies | 89/26% | N/A |
| Berger et al. (2014) [9] | 52 cancer patients who died within 30 days of RT | 2009–2011 | All histologies | N/A | 41 (78%) |
| Toole et al. (2012) [17] | 63 cancer patients who died shortly after RT | 2008–2011 | All histologies | 63 (100%) | 33 (52%) |

Abbreviations: CT — Chemotherapy; EOL — End of life; N/A — Not available; RCT — Radio-Chemo-Therapy; RT — Radiotherapy; and RTD — Radiotherapy within 30 days of death.

Tumor board involvement

Of note, only 38% of RT decisions were discussed in an organ-specific tumor board. This rather low rate may be due to the fact that palliative RT indications, especially for pain control or airway management, are typically summoned under symptom management, which does not necessarily require interdisciplinary involvement, potentially allowing for a quicker RT initiation.

Shortcomings

Limitations of this study arise from its retrospective nature. The results do not lend themselves to causal inferences. Also, other university centers may see different practices and a different patient mix, though they all tend to care for patients with advanced, incurable cancer. The lack of systematic assessment of patient reported outcomes, which represents a general challenge in studies with a palliative patient cohort, is a further shortcoming. Overall, despite its limitations, this study sheds light on the highly personalized and patient-centered decision-making at the EOL in our department, where treating radiation oncologists are often confronted with severely ill patients demanding treatment while having to weigh various aspects for and against RT in the absence of reliable prognostic scoring systems.

Conclusion

Survival prognosis and patient selection for EOL RT remains challenging for radiation oncologists. While EOL RT until one week before death was characterized by high completion and treatment benefit rates, which were almost comparable to RT administered within 60–30 days of death, treatment prescribed within one week of death, often had to be discontinued. The utilization of EOL RT therefore needs to be carefully weighed, also taking into account patient preferences for and against RT in the absence of life.

Funding

Caroline Hertler obtained funding by the “Filling the Gap” program, Faculty of Medicine, University of Zurich, Switzerland.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Lust S, Korytko T, Nguyen J, Khan L, Chow E, Corn B. Palliative radiotherapy when is it worth it and when is it not? Cancer J 2010;16(5):473–62. https://doi.org/10.1097/PPO.0b013e3181f28b46.

[2] Jones JA, Lust ST, Chow E, Johnston PA. Palliative radiotherapy at the end of life: a critical review. A Cancer J Clin 2014;64(5):290–310. https://doi.org/10.3322/1530-5898/2014.04.00321.

[3] Chow E, Zeng L, Salvo N, Dennis K, Tran M, Lust S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (Internet) 2012;24(3):191–24. https://doi.org/10.1016/j.clon.2011.11.005.

[4] Hernane R, Montero A, Fernandez-Lizarrabe A, Polo A, Ramos A. Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases. Clin Transl Oncol 2015;17(1):172–8. https://doi.org/10.1007/s11599-014-0895-y.

[5] Tseo MN. Brain metastases: advances over the decades. Am J Palliat Med 2015;34(4):225–32. https://doi.org/10.1097/PMR.0000000000000191.

[6] Graege M, Eoong J, Qian Y, Sandhu N, Liu Y, Turner B, et al. Outcomes and characteristics of patients treated with emergent palliative whole brain radiotherapy. Pract Radiat Oncol. [Internet] 2019;9(2):203–9. https://doi.org/10.1016/j.prro.2018.11.008.

[7] Tseng TD, Kristiansen MS, Sullivan AJ, Jones JA, Chow E, Balboni TA. How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: a survey-based study. Radiat Oncol Biol [Internet] 2015;5(7):471–8. https://doi.org/10.1016/j.rorb.2015.05.2046.

[8] Grigas K, Mulsian S, Ruoke E, Willis P. Palliative radiotherapy tailored to life expectancy in end stage cancer patients. Cancer Treatment Reviews 2010;11(15):3251–6. https://doi.org/10.1016/j.cancer.2010.05.028.

[9] Berger B, Ansel K, Rumborg M, Zipe D. Patients who die during palliative radiotherapy. 2014;September 2013:217–20. DOI: 10.1007/000066-013-0471-6.

[10] Guadagnolo BA, Liao K, Elting L, Giordano S, Buchholz TA, Shih YT. Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the united states methods. J Clin Oncol 2013;31(1):907–11. https://doi.org/10.1002/jco.2012.45.0585.

[11] Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five for oncology. J Clin Oncol 2012;30(14):1715–24. https://doi.org/10.1002/jco.2012.41.075.

[12] Perpererom JM, Smith TJ, Helft PR, Delbono DJ, Berry SR, Wellins DS, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2012;29(9):555–69. https://doi.org/10.1200/jco.2012.44.1744.

[13] European Society for Medical Oncology (ESMO). ESMO Clinical Practice Guidelines: Supportive and Palliative Care. 2019.

[14] World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization. 2018. ISBN: 978-92-4-150099-0.

[15] Wu SY, Singer L, Boecla L, Garcia MA, Fugh B, Braamstein SE. Palliative radiotherapy near the end of life. BMC Palliat Care 2015;18(29):4–11. https://doi.org/10.1186/s12904-019-0415-3.

[16] Meruse JH, van der Linden YM, van Tienhoven G, Ganz BOB, Leer JWH, Reinders ARL. Efficiency of radiotherapy for painful bone metastases during the last 12 weeks of life. Cancer 2010;NA. https://doi.org/10.1002/1058-2074.

[17] Toole M, Lust S, Johnston PA. Radiation oncology quality: aggressiveness of cancer care near the end of life. J Am Coll Radiol [Internet] 2012;9(3):199–202. https://doi.org/10.1016/j.acra.2011.11.005.

[18] Aushahmou G, Gumnid MA, Kusno S, Kivakos A, Granten BH. Characterisation of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway. Acta Oncol (Malta) 2015;54(5):393–401. https://doi.org/10.3109/0284186X.2014.948061.

[19] Hoehn CHM, Spruit MA, Groenen MTJ, Wouters EFM, Jansma DJA. Efficiency of advance care planning: a systematic review and meta-analysis. J Am Med Dir Assoc [Internet] 2014;15(10):777–87. https://doi.org/10.1016/j.jamda.2014.01.008.

[20] Reich O, Signorell A, Ruso A. Place of death and health care utilization for people in the last 6 months of life in Switzerland: a retrospective analysis using administrative data. BMC Health Serv Res 2013;13(1021–10).

[21] Ellsworth SG, Alcorn SR, Hales RK, Menut TR, Deweese TL, Smith TJ. Patterns of care among patients receiving radiation therapy for bone metastases at a large academic institution. Radiat Oncol Biol [Internet] 2014;44(9):1100–5. https://doi.org/10.1016/j.jrobp.2014.04.006.